Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients

International Journal of COPD

Volumn 3, Issue 1, 2008, Pages 127-136

  Kesten, Steven ^a   Casaburi, Richard ^b   Kukafka, David ^c   Cooper, Christopher B ^d  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c Northern Colorado Pulmonary Consultants PC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activity; Chronic obstructive pulmonary disease; Exercise; Pulmonary rehabilitation; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; OXYGEN; PLACEBO; SALBUTAMOL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYCLING; DOUBLE BLIND PROCEDURE; ENDURANCE; EXERCISE; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; JOGGING; MAJOR CLINICAL STUDY; MALE; PULMONARY REHABILITATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ROWING; SELF REPORT; SPIROMETRY; STATISTICAL SIGNIFICANCE; SWIMMING; TASK PERFORMANCE; TREADMILL EXERCISE; WALKING;

AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; EXERCISE; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HEALTH BEHAVIOR; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SELF ASSESSMENT (PSYCHOLOGY);

EID: 42149136242     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Aalbers R, Ayres J, Backer V, et al. 2002. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J, 19:936-43.
2. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. 1997. ACCP/AACVPR Pulmonary Rehabilitation Guidelines. Chest, 112:1363-96.
3. Casaburi R, Kukafka D, Cooper CB, et al. 2005. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest, 127:809-17.
4. Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19:217-24..
5. Celli BR, MacNee W, and ATS/ERS Task Force Committee Members. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
6. Celli B, Zu Wallack R, Wang S, et al. 2003. Improvements in resting inspiratory capacity and hyperinflation with tiotropium in COPD with increased static lung volumes. Chest, 124:1743-8.
7. [GOLD] Global Initiative for Chronic Obstructive Lung Disease. 2005. NHLBI/WHO Workshop Report [online]. 2001, Update 2005. Accessed November 10, 2005. URL: http://www.goldcopd.com.
8. Guyatt GH, Berman LB, Townsend M, et al. 1987. A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42:773-8.
9. Jones PW, Quirk FH, Baveystock CM, et al. 1992. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis, 145:1321-7.
10. Mahler DA, Weinberg DH, Wells CK, et al. 1984. Baseline dyspnoea index and transitional dyspnoea index: The measurement of dyspnoea. Chest, 85:751-8.
11. Maltais F, Hamilton A, Marciniuk D, et al. 2005. Improvements in symptom-limited exercise performance over eight hours with once-daily tiotropium in patients with COPD. Chest, 128:1168-78.
12. Morris JF, Koski A, Temple WP, et al. 1988. Fifteen year interval spirometric evaluation of the Oregon predictive equations. Chest, 93:123-7.
13. O'Donnell D, Flüge T, Gerken F, et al. 2004a. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J, 23:832-40.
14. O'Donnell DE, Voduc N, Fitzpatrick M, et al. 2004b. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J, 24:86-94.
15. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:1087-92.
16. Weaver TE, Narsavage GL. 1992. Physiological and psychological variables related to functional status in chronic obstructive pulmonary disease. Nurs Res, 41:286-91.